Researchers found that a new drug called Retevmo (selpercatinib) significantly reduces the risk of disease recurrence or death in people with early-stage RET fusion-positive lung cancer. In a recent clinical trial, this targeted therapy demonstrated an impressive 83% reduction in risk compared to a placebo, making it a promising option for individuals facing this aggressive form of cancer.

This discovery is particularly important for those diagnosed with early-stage RET fusion-positive lung cancer, a group that has previously lacked effective treatment options. The trial showed that after two years, 92% of patients taking Retevmo were free from disease recurrence, compared to only 61% of those on placebo. This could mean a longer, healthier life for patients, as effective adjuvant therapies can help prevent cancer from returning after initial treatment.

The evidence comes from a Phase 3 clinical trial, which involved 151 patients who received Retevmo or a placebo after surgery or radiation therapy. The results are strong, but it’s important to note that the overall survival data are still immature, meaning more research is needed to confirm long-term benefits. While the safety profile of Retevmo aligns with previous studies, some patients experienced significant liver-related side effects that require monitoring.

If you or someone you know is dealing with early-stage lung cancer, discussing comprehensive biomarker testing with a healthcare provider could be beneficial. This testing can help identify if RET fusions are present and whether Retevmo might be an appropriate treatment option.

Source: investor.lilly.com